Sep 14, 2026 08:02AM
Sep 14, 2026 08:00AM
Aug 5, 2026 04:05PM
Aug 3, 2026 08:00AM
Aug 3, 2026 08:00AM
Jun 30, 2026 08:02AM
Jun 30, 2026 08:00AM U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
Jun 10, 2026 08:02AM
Jun 10, 2026 08:00AM
May 7, 2026 07:00AM
May 4, 2026 08:04AM
May 4, 2026 08:00AM
Apr 14, 2026 10:59AM
Apr 13, 2026 08:03AM Akebia begins dosing patients in Phase 1 trial of AKB-9090
Apr 13, 2026 08:00AM
Apr 1, 2026 04:05PM
Apr 1, 2026 04:05PM
Mar 19, 2026 04:05PM
Feb 26, 2026 07:00AM
Jan 12, 2026 08:02AM
Jan 12, 2026 08:00AM Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook
Jan 6, 2026 08:01AM
Jan 6, 2026 08:00AM
Dec 1, 2025 07:00AM
Nov 10, 2025 07:00AM
Nov 6, 2025 06:30PM
Oct 28, 2025 04:30PM
Oct 28, 2025 04:30PM Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients
Oct 20, 2025 08:08AM
Aug 21, 2025 08:01AM
Aug 21, 2025 08:00AM
Aug 7, 2025 07:00AM
Aug 4, 2025 08:00AM
Jun 4, 2025 08:01AM
Jun 4, 2025 08:00AM Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology
May 8, 2025 07:00AM
Apr 3, 2025 08:01AM
Apr 3, 2025 08:00AM
Mar 13, 2025 07:00AM
Jan 13, 2025 08:06AM
Jan 13, 2025 08:00AM
Dec 3, 2024 07:00AM U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis
Nov 14, 2024 08:00AM
Nov 7, 2024 07:00AM
Oct 22, 2024 08:03AM
Oct 22, 2024 08:00AM
Oct 15, 2024 08:00AM
Oct 11, 2024 06:37AM
Oct 10, 2024 08:02AM Akebia Therapeutics (AKBA) Reports CMS Grants TDAPA Reimbursement for Vafseo beginning January 1, 2025
Oct 10, 2024 08:00AM

331,927 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All